Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. (RGLS), sold 8,750 shares at $7.19 ($62K) on 2014-09-24, disclosed to the SEC on 2014-09-26.
Scheduled sale ($62k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.19 | 3,750 | $27K | 43.2% |
| 2 | $7.12 | 2,500 | $18K | 28.5% |
| 3 | $7.04 | 2,500 | $18K | 28.2% |
| Total | $7.13 avg | 8,750 | $62K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |